| Literature DB >> 35352014 |
David Rogerson1,2, Fabio Alejandro Aguilar Mora2,3, Jamie Stuart Young4, Markos Klonizakis5.
Abstract
BACKGROUND/Entities:
Mesh:
Substances:
Year: 2022 PMID: 35352014 PMCID: PMC9550618 DOI: 10.1038/s41430-022-01115-4
Source DB: PubMed Journal: Eur J Clin Nutr ISSN: 0954-3007 Impact factor: 4.884
Fig. 1Study design and procedures.
Consolidated standards of reporting trials (CONSORT) flow diagram showing participant flow throughout the study.
Baseline anthropometric and blood pressure data: pre-treatment comparison between Young (n = 17) vs. Old (n = 7) participants prior to administration of NO3 supplementation.
| YOUNG ( | OLD ( | |||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| Age (y)* | 24.2 | 3.5 | 68.7 | 10.3 |
| 0.000 | ||||
| Stature (cm) | 168.3 | 7.9 | 168.3 | 10.2 |
| 0.997 | ||||
| Body mass (kg) | 62.7 | 12 | 76.7 | 20.7 |
| 0.193 | ||||
| BMI (kg m2)** | 22.7 | 2.8 | 26.7 | 5.1 |
| 0.019 | ||||
| WC (cm)** | 78.8 | 8.1 | 96.4 | 15.8 |
| 0.001 | ||||
| Body fat (%) | 15.9 | 5.9 | 22.9 | 11.4 |
| 0.051 | ||||
| SBP (mmHg) | 106.8 | 20 | 115.1 | 28.4 |
| 0.415 | ||||
| DBP (mmHg)** | 66.8 | 9.9 | 81.3 | 10.9 |
| 0.004 | ||||
| RHR (bpm)** | 67.8 | 14.9 | 96 | 42.5 |
| 0.020 | ||||
Independent-samples t-test reveals between-groups differences at the 0.001 (*) and 0.005 level (**) for Age*, BMI**, WC**, DBP** and RHR**.
WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, RHR resting heart rate.
Fig. 2Blood pressure and heart rate following Treatment vs. Placebo.
Three-way mixed ANOVA, with two between groups (Treatment vs. Placebo and Age [Young/Group A vs. Old/Group B]) and one within group factor (time), revealed no effects of NO3 supplementation (P > 0.05) for Group A (Young: n = 17) nor Group B (Old: n = 7).
Difference between placebo vs. nitrate blood pressure, heart rate and skin blood flow responses in Young (n = 17) vs. Old (n = 7) participants.
| YOUNG ( | OLD ( | |||
|---|---|---|---|---|
| Mean | SD | Mean | SD | |
| Δ SBP | −0.74 | 1.3 | 30.4 | 8 |
| Δ DBP | 1.4 | 1 | 16 | 4 |
| Δ HR | 0.4 | 1.1 | −1.2 | 4.6 |
| CVC Baseline* | ||||
| Δ Nitrate | 2.6 | 6.9 | 6.1 | 5.5 |
| Δ Placebo | 3.9 | 3.8 | −1 | 6.5 |
| CVC Initial Peak | ||||
| Δ Nitrate | 16.2 | 43.9 | 9.7 | 25.8 |
| Δ Placebo | 17.5 | 28.4 | −1 | 40.9 |
| CVC Plateau | ||||
| Δ Nitrate | −1.9 | 11.4 | −2.4 | 7.4 |
| Δ Placebo | −5.2 | 10.9 | −1.5 | 6.6 |
Statistically significant interaction at the P ≤ 0.05 level (*) observed between age and treatment for CVC at baseline (P = 0.037) only.